Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1,174.85% | 231.45% | 251.45% | 387.44% | |
| (147.62%) | (328.86%) | (290.88%) | (304.47%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(131.93%) | (294.93%) | (326.65%) | (329.55%) | |
Average Days of Receivables |
260.08 | 21.83 | 243.53 | 158.54 | |
Free Cash Flow per Share |
(2.45) | (4.06) | (3.08) | (3.00) | |
Free Cash Flow |
(21.04) | (30.37) | (33.68) | (34.98) | |
Capital Expenditures |
(0.09) | (0.13) | (0.22) | (0.22) | |
| Other line items | |||||
Cash ROIC |
(36.39%) | 30.83% | 19.67% | 30.00% | |
Accounts Receivable Turnover |
0.49 | 2.53 | 1.96 | 3.04 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
713.76% | 844.55% | 428.81% | 300.38% | |
Selling, General and Administrative Expense of Revenue |
441.87% | 466.03% | 244.94% | 184.90% | |
Share Based Compensation of Revenue |
103.58% | 110.30% | 68.13% | 60.85% | |
Operating CF/Net income |
0.20 | 0.13 | 0.10 | 0.10 | |
Depreciation/Fixed assets |
5.86 | 1.24 | 0.63 | 0.49 | |
Capex/Depreciation |
(0.11) | (0.24) | (0.72) | (1.00) | |
Revenue per Share |
0.42 | 0.47 | 0.68 | 0.99 | |
Operating CF per Share |
(2.44) | (4.04) | (3.06) | (2.98) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
0.02 | 0.04 | 0.03 | 0.02 |
Columns are period end dates